Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
ADA, addressed, advice, Alaska, Amira, autotaxin, awaiting, BRAF, classification, closeout, committed, cyclosporine, dasatanib, donor, EFFERALGAN, Endocrinologic, exploratory, fibrotic, indefinitely, inflammatory, Innate, ischemic, ISTH, KOMBOGLYZE, lead, lysophosphatidic, medical, Metabolic, mutant, neuropathic, pain, passed, Pharma, preclinical, RAF, RAS, recovery, Roche, sugar, sulfonylurea, switched, topline, tradename, unchanged, unspecified, vermurafenib, voted, VTE, XR
Removed:
aggregated, Allergan, aspirin, barring, BioPharma, bundled, caption, cell, coincide, comprised, cycle, detail, diagnosed, Division, dosage, dose, elimination, experimental, extent, fall, indirect, individually, introducing, invested, maximum, Mexico, minimum, monitored, newly, Ohio, outflow, PDL, permanent, pharmacy, plasma, production, reducing, reinvestment, retiree, Sherman, solid, submitted, unsuitable, VA, validated, vendor, welfare, Western, world
Filing tables
Filing exhibits
Related press release
BMY similar filings
Filing view
External links